MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers
Gastrointestinal cancer accounts for the 20 most frequent cancer diseases worldwide and there is a constant urge to bring new therapeutics with new mechanism of action into the clinical practice. Quantity of in vitro and in vivo evidences indicate, that exogenous change in pathologically imbalanced...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Frontiers Media S.A.,
2016-09-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_0d6cc8ccbbfe4e08a98b7e5163b31175 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Jana Merhautova |e author |
| 700 | 1 | 0 | |a Regina Demlova |e author |
| 700 | 1 | 0 | |a Regina Demlova |e author |
| 700 | 1 | 0 | |a Ondrej Slaby |e author |
| 700 | 1 | 0 | |a Ondrej Slaby |e author |
| 245 | 0 | 0 | |a MicroRNA-based Therapy in Animal Models of Selected Gastrointestinal Cancers |
| 260 | |b Frontiers Media S.A., |c 2016-09-01T00:00:00Z. | ||
| 500 | |a 1663-9812 | ||
| 500 | |a 10.3389/fphar.2016.00329 | ||
| 520 | |a Gastrointestinal cancer accounts for the 20 most frequent cancer diseases worldwide and there is a constant urge to bring new therapeutics with new mechanism of action into the clinical practice. Quantity of in vitro and in vivo evidences indicate, that exogenous change in pathologically imbalanced microRNAs (miRNAs) is capable of transforming the cancer cell phenotype. This review analyzed preclinical miRNA-based therapy attempts in animal models of gastric, pancreatic, gallbladder, and colorectal cancer. From more than 400 original articles, 26 was found to assess the effect of miRNA mimics, precursors, expression vectors, or inhibitors administered locally or systemically being an approach with relatively high translational potential. We have focused on mapping available information on animal model used (animal strain, cell line, xenograft method), pharmacological aspects (oligonucleotide chemistry, delivery system, posology, route of administration) and toxicology assessments. We also summarize findings in the field pharmacokinetics and toxicity of miRNA-based therapy.□ | ||
| 546 | |a EN | ||
| 690 | |a Mice | ||
| 690 | |a microRNA | ||
| 690 | |a colorectal cancer | ||
| 690 | |a animal model | ||
| 690 | |a Pancreatic Cancer | ||
| 690 | |a gastric cancer | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Frontiers in Pharmacology, Vol 7 (2016) | |
| 787 | 0 | |n http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00329/full | |
| 787 | 0 | |n https://doaj.org/toc/1663-9812 | |
| 856 | 4 | 1 | |u https://doaj.org/article/0d6cc8ccbbfe4e08a98b7e5163b31175 |z Connect to this object online. |